Synthesis and Applications of Carbon Dots

近年来,由于碳纳米材料具有高的催化活性以及好的稳定性等优点,其在科学、工程以及商业领域都得到了广泛的应用。其中新型“零维“碳纳米材料——碳量子点(CArbOn dOTS,CdS)具有荧光信号稳定、无光闪烁、激发波长和发射波长可调控等独特的光学性质,以及生物毒性小和生物相容性好等优势,逐渐成为碳纳米材料的研究热点,广泛应用于生物成像、生物细胞标记、传感器、光催化、太阳能电池以及发光元件等领域。本文主要综述了CdS的不同合成方法(包括自上而下法和自下而上法)及其应用。In recent years,nanomaterials have made an important impact on diverse science,engineering,and commercial sectors due to their high catalysis,lowcost,and good stability.Acting as a class of ‘zero-dimensional'carbon nanomaterials,carbon dots( CDs) possess unique optical properties of high photostability against photobleaching,tunable excitation and emission wavelength,as well as lowcytotoxicity and good biocompatibility.Therefore,CDs have become a hot subject of carbon nanomaterial in the past decade,not only for its unique properties but also for its applications in various fields such as bioimaging,biolabeling,sensors,photocatalysis,solar cells, light-emitting element and so on.This article reviews the different synthetic methodologies( including two classes: top-down and bottom-up) to achieve good performance of CDs.At the same time,the applications of CDs are also reviewed in the article.国家质检总局科技计划项目(No.2012QK053); 福建省质量技术监督局科技项目(No.3002A91429); 福建省高校产学合作科技重大项目(No.2012H6026); 福建省自然科学基金项目(No.2012D136); 福建省教育厅科技项目(No.JB14180)资助~

hrHPV DNA载量 分型和E6蛋白对宫颈癌前病变进展的预测作用

目的:探讨预测高危型人乳头瘤病毒(high risk human papillomavirus,hrHPV)阳性和宫颈上皮内瘤样病变1级(cervical in-traepithelial neoplasia grade 1,CIN1)妇女进展的生物学标志物。方法:2010年10月至2012年8月在山西省、河南省和江西省招募7 543名妇女,采用hrHPV DNA检测和E6蛋白检测(Onco E6)等方法进行宫颈癌筛查,任一结果阳性者转诊阴道镜并取活检,于1年后随访。纳入基线hrHPV阳性或病理诊断CIN1者。结果:共纳入794例满足条件妇女,1年后88例妇女病理级别发生进展。基线hrHPV DNA中高载量者进展的风险是低载量者的2.9倍(95%CI为1.8~4.8),hrHPV16/18/45、E6蛋白阳性者进展的风险分别是阴性者的2.4倍(95%CI为1.5~3.9)、2.9倍(95%CI为1.5~5.9),其进展至宫颈上皮内瘤样病变2级及以上(cervical intraepi-thelial neoplasia grade 2 or worse,CIN2+)的绝对风险分别为4.9%(95%CI为3.2~7.4)、9.0%(95%CI为5.5~14.3)、18.8%(95%CI为10.2~31.9)。hrHPV16/18/45中高载量且E6蛋白(Onco E6)阳性妇女进展的绝对风险高达32.4%(11/34)。结论:hrHPV DNA中高载量、hrHPV16/18/45分型以及E6蛋白(Onco E6)可作为妇女hrHPV阳性和CIN1进展的生物学标志物,特别是hrHPV中高载量且E6蛋白(Onco E6)阳性妇女,临床应给予密切随访。中国医学科学院医学与健康科技创新工程重大协同创新项目(编号:2016-I2M-1-019)资助~

用于视觉修复的视网膜下植入微芯片

为治疗由视网膜光感受器退化引起的失明，研制了一种可以满足视网膜下植入要求的光电刺激器件——硅基PIN光电探测器阵列结构微芯片，这种电刺激芯片可以在一定程度上代替因疾病受损的光感受细胞，向位于光感受细胞之后、尚未损伤的其他视网膜细胞发出电刺激，从而引发视神经的视觉冲动。微芯片制作采用了硅、硅氧化物以及金等生物相容性较好的材料。在微芯片上利用半导体工艺刻蚀隔离槽，形成一个探测器面阵，面阵上的每个探测器单元可以根据照射在其上的光强大小产生相应的刺激电流。对制作的芯片进行了生物相容性、伏安特性、响应度以及光谱特性的测量，结果表明，芯片在眼睛安全用光的范围内可以产生足够强度的刺激电流，满足动物植入实验的要求

正常及光感受器损伤兔眼视网膜下芯片植人后的电生理结果

目的 观察视网膜下芯片所引起的光感受器损伤及正常兔眼的电生理改变。方法 青紫蓝兔共30只，其中22只兔NaIO_3生理盐水溶液静脉注人后眼光感受器受到损伤。将一个由90个微光电二极管组成的阵列和相连电极构成的直径约3 mm的芯片通过巩膜切口植人4只正常及22只注药后光感受器损伤兔右眼的视网膜下腔或脉络膜中,左眼为对照眼;分别检测芯片眼及对照眼局部闪光视觉诱发电位（F-VEP)、局部闪光视网膜电图(F-ERG)、全视野闪光VEP及全视野闪光ERG.另外4只兔双眼摘作病理检查。结果 22只色光感受器损伤兔中有11只芯片眼的局部ERG主波振幅明显大于对照眼；4只正常兔中，2只芯片眼的局部ERG主波振幅大于对照眼。1只芯片眼表面视网膜出现破孔不能引出任何波。局部VEP及全视野闪光VEP重复性较差，全视野闪光ERG未见明确差别。结论 植人的芯片在受到光刺激后可刺激局部视网膜并引起局部视网膜的电活动

绿色农业新技术集成研究与示范

一、该项目针对农业生产中食品安全和环境污染问题,开展了S-诱抗素、新奥霉素、壳寡糖、棉铃虫病毒杀虫剂与昆虫病原线虫生物制剂、功能性堆肥及其浸提液工业化生产等的试验和示范,立项准确,针对性强,意义重大。 二、项目研究出S-诱抗素等生物制剂及其生产工艺、工厂化技术;研究开发出昆虫病原线虫活体繁殖技术,实现了工厂化生产;研究开发了两种功能性堆肥及浸提液,提出了“功能性堆肥+秸秆生物反应堆+堆肥浸提液+S-诱抗素等生物制剂”健康、安全设施蔬菜生产模式;在宁夏实现了地上、地下,土壤、作物生物制剂联防技术体系,为低耗、高效、安全、健康农产品生产开辟了新途径。 三、在S-诱抗素、新奥霉素高产菌株的生产工艺,昆虫病原线虫活体繁殖工厂化生产方面取得了新突破;在S-诱抗素、新奥霉素、壳寡糖、棉铃虫病毒杀虫剂、功能性堆肥及其浸提液集成应用控制作物病虫害等方面有创新。研究成果达到了国内先进水平,S-诱抗素、新奥霉素高产菌株的生产工艺研究达到国际领先。 四、项目执行期间,在宁夏15个市县建立核心试验基地14个,示范推广点40个,累计推广面积17万亩,新增效益9600万元。获得发明专利4项,实用新型专利1项,制定地方标准5项,专著1部,发表论文19篇(其中SCI收录6篇)。培训农技人员300人次,农民4700多人次

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel